- Home
- PHAR vs ITRN Comparison
PHAR vs ITRN Comparison
Compare PHAR & ITRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | ITRN |
|---|---|---|
| Founded | 1988 | 1994 |
| Country | Netherlands | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 866.1M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | PHAR | ITRN |
|---|---|---|
| Price | $17.21 | $43.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $38.00 | ★ $50.00 |
| AVG Volume (30 Days) | 24.0K | ★ 107.1K |
| Earning Date | 11-06-2025 | 11-18-2025 |
| Dividend Yield | N/A | ★ 4.62% |
| EPS Growth | N/A | ★ 8.81 |
| EPS | 0.00 | ★ 2.84 |
| Revenue | ★ $362,274,000.00 | $348,409,000.00 |
| Revenue This Year | $25.19 | $9.12 |
| Revenue Next Year | $4.47 | $10.70 |
| P/E Ratio | $3,041.40 | ★ $15.22 |
| Revenue Growth | ★ 26.78 | 5.20 |
| 52 Week Low | $7.50 | $29.47 |
| 52 Week High | $18.12 | $45.43 |
Technical Indicators
Market Signals| Indicator | PHAR | ITRN |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 61.56 |
| Support Level | $16.98 | $41.58 |
| Resistance Level | $17.00 | $43.91 |
| Average True Range (ATR) | 0.71 | 1.22 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 98.48 | 69.30 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ITRN Ituran Location and Control Ltd.
Ituran Location and Control Ltd is a provider of location-based services. The company operates in two segments, namely Telematics services and Telematics products. The Telematics services segment consists of regionally-based stolen vehicle recovery (SVR) services, fleet management services, and value-added services comprised of personal locater services and concierge services. The Telematics product segment consists of short and medium-range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location and automatic vehicle identification. Its geographical segments include Israel, Brazil, and Others. The company derives maximum revenue from Israel.